Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

ABSTRACT:

Purpose

Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to perform an exploratory study analyzing the implication of single nucleotide polymorphisms (SNPs) on outcomes from this treatment through a pharmacogenetic analysis.

Patients and methods

Blood was collected from 90 postmenopausal women with hormone receptor-positive, HER2-negative MBC treated with exemestane-everolimus following progression after prior treatment with a non-steroidal aroma

SUBMITTER: Pascual T 

PROVIDER: S-EPMC5519037 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature